ArticleBMJ open2026

Phase Ib/II trial to evaluate the safety and efficacy of atezolizumab and bevacizumab as adjuvant therapy following carbon-ion radiotherapy in hepatocellular carcinoma (VANGUARD): study protocol.

Keisuke Koroki et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.